Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
` UNITED STATES PATENT AND TRADEMARK OFFICE
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
` CASE NO.: IPR2013-00401
` Patent 5,527,533
`
`CYANOTECH CORPORATION,
` Petitioner,
`vs.
`THE BOARD OF TRUSTEES
`OF THE UNIVERSITY OF
`ILLINOIS,
` Patent Owner.
`___________________________________/
`
`DEPOSITION OF: Shalesh Kaushal, M.D., Ph.D.
`DATE TAKEN: May 2, 2014
`TIME: 9:09 a.m. - 4:13 p.m.
`PLACE: Hilton - University of Florida
` Conference Center
` 1714 S.W. 34th Street
` Gainesville, Florida 32607
`REPORTED BY: Lori Francis, RPR, FPR and
` Notary Public
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`800.939.0093
`CYAN EXHIBIT 1079
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
` UNITED STATES PATENT AND TRADEMARK OFFICE
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
` CASE NO.: IPR2013-00401
` Patent 5,527,533
`
`CYANOTECH CORPORATION,
` Petitioner,
`vs.
`THE BOARD OF TRUSTEES
`OF THE UNIVERSITY OF
`ILLINOIS,
` Patent Owner.
`___________________________________/
`
`DEPOSITION OF: Shalesh Kaushal, M.D., Ph.D.
`DATE TAKEN: May 2, 2014
`TIME: 9:09 a.m. - 4:13 p.m.
`PLACE: Hilton - University of Florida
` Conference Center
` 1714 S.W. 34th Street
` Gainesville, Florida 32607
`REPORTED BY: Lori Francis, RPR, FPR and
` Notary Public
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`800.939.0093
`CYAN EXHIBIT 1079
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 2
`APPEARANCES:
`
` APPEARING ON BEHALF OF THE PETITIONER:
` JOHN A. BOUDET, ESQUIRE
` Roetzel & Andress, LPA
` 420 South Orange Avenue
` 7th Floor
` Orlando, Florida 32801
` jboudet@ralaw.com
`
` GEORGE DARBY, ESQUIRE
` Darby Law Corporation
` 95-1045 Alakaina Street
` Mililani, Hawaii 96789
` darbypatent@teleport-asia.com
`
` APPEARING ON BEHALF OF THE PATENT OWNER:
` TODD S. WERNER, ESQUIRE
` Carlson, Caspers, Vandenburgh,
` Lindquist & Schuman, P.A.
` 225 South Sixth Street
` Suite 4200
` Minneapolis, Minnesota 55402
` twerner@carlsoncaspers.com
`
`
`
`
`
`
`ALSO PRESENT: John Minatelli, Ph.D.
` Steve Hill
`
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 3
`
` I N D E X
` EXAMINATIONS
` DIRECT CROSS REDIRECT RECROSS FURTHER
`Mr. Darby 6 144
`Mr. Werner 136
`
`Certificate of Reporter........................... 149
`Certificate of Oath............................... 150
`Errata Sheet...................................... 151
`Read and Sign Letter.............................. 152
`
` EXHIBITS
` Page Line
`Cyan Exhibit 1050............................ 35 24
`(Article from Nature Genetics)
`Cyan Exhibit 1051............................ 39 21
`(Article from Experimental Eye Research - 2013)
`Cyan Exhibit 1052............................ 41 21
`(Article from The Journal of Neuroscience)
`Cyan Exhibit 1053............................ 49 14
`(Article from Investigative Ophthalmology
`& Visual Science - Friedenwald Lecture)
`Cyan Exhibit 1054............................ 72 20
`(Article from Comparative Biochemistry
`& Physiology)
`
`1
`2
`3
`4
`5
`
`6 7
`
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 4
`Cyan Exhibit 1055............................ 107 21
`(Article from Molecular Vision)
`Cyan Exhibit 1056............................ 110 5
`(Article from Experimental Eye Research - 2003)
`Cyan Exhibit 1057............................ 112 6
`(Article from the American Academy
`of Ophthalmology)
`Cyan Exhibit 1058............................ 121 10
`(Article from Canadian Journal of
`Physiology & Pharmacology)
`Cyan Exhibit 1059............................ 123 12
`(Article from Transactions of the American
`Ophthalmological Society on - 1990)
`Cyan Exhibit 1060............................ 126 3
`(Article from Eye)
`Cyan Exhibit 1061............................ 127 17
`(Article from Age and Ageing)
`Cyan Exhibit 1062............................ 128 6
`(Article from Transactions of the American
`Ophthalmological Society - 1987)
`Cyan Exhibit 1063............................ 129 12
`(Article from Brain Research)
`Cyan Exhibit 1064............................ 130 7
`(Article from American Journal of Hematology)
`Cyan Exhibit 1065............................ 132 1
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 5
`
`(Article from Journal of Free Radicals in
`Biology and Medicine)
`Cyan Exhibit 1066............................ 132 15
`(Article from The Jouranl of Biological
`Chemistry)
`
` (Previously marked Cyan Exhibits 1001, 1002, 1004,
`1008, 1010, 1012, 1014, 1020, 1025, 1026 and University
` Exhibit 2015 have been attached.)
`
`1
`2
`3
`4
`5
`
`6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 6
`
` P R O C E E D I N G S
` SHALESH KAUSHAL, M.D., Ph.D.,
`having been first duly sworn to tell the truth, was
`examined and testified upon his oath as follows:
` THE WITNESS: Yes.
` DIRECT EXAMINATION
`BY MR. DARBY:
` Q Thank you, Lori.
` Dr. Kaushal, I'm George Darby. I'll be
`asking the questions today.
` A Yes.
` Q First thing I'd like to confirm is whether
`you need to take breaks more frequently than once an
`hour.
` A That's fine.
` Q Okay.
` A I'm on call, so I may every once in a while
`need to look at my cell phone.
` Q Sure.
` A But I put it on silent mode.
` Q Vibrate. Well, if we see you jump, we'll
`know what's happening.
` A Right.
` Q Since we don't have video, it's easy to
`start and stop, so just say -- raise your hand and say
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 7
`
`I need a break.
` A Okay. Sounds great.
` Q Okay. Some sort of formal questions at the
`beginning, do you have a financial interest in the
`outcome of the case?
` A No, I don't.
` Q Okay. Do you have a financial interest in
`the Tso patent, which I'll refer to --
` A No.
` Q -- as the 533 patent, US patent No.
`5,527,533?
` Do you receive royalties from the patent?
` A No, I don't.
` Q Do you have a consulting agreement or any
`other agreement with the University of Illinois?
` A No, I don't.
` Q Do you have an agreement with Valensa
`International?
` A No, I don't.
` Q Does University of Illinois fund any of your
`projects --
` A No.
` Q -- research projects?
` Does Valensa fund any of the research
`projects?
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 8
`
` A No.
` Q Does the University of Illinois -- you are
`employed in a medical practice?
` A Yes.
` Q Does the University of Illinois fund
`anything at your medical practice?
` A No.
` Q Do you have other hats that you wear, a
`consulting company?
` A Yes.
` Q Okay. Does the University of Illinois fund
`any of your projects at your consulting company?
` A No, they don't.
` Q Valensa -- does Valensa fund anything at
`your medical practice?
` A No.
` Q Does Valensa fund anything at your
`consulting companies?
` A No.
` Q May I ask what your compensation is for your
`work as an expert witness in this case?
` A Yes. I receive $450 per hour.
` Q Thank you.
` Without disclosing the substance of the
`discussions, did you confer with plaintiff's attorneys
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 9
`
`about the 533 patent before the deposition?
` A Yes.
` Q Okay. Do you have attorneys other than --
`or did you confer with attorneys other than University
`of Illinois attorneys?
` A No.
` Q Did you confer with anyone else about the
`533 patent before the deposition?
` A No.
` Q Have you ever talked with Dr. Moerck at
`Valensa?
` A No.
` Q I guess you've talked with Dr. Minatelli
`since he's here today.
` A Right.
` Q And did those conversations involve the 533
`patent?
` A In a limited way.
` Q Did those conversations involve your
`declaration in the patent owner's response to the IPR?
` A No.
` Q Have you ever corresponded with anyone
`else -- I said talked before.
` Have you ever corresponded with anyone else
`about the 533 patent?
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 10
`
` A No.
` Q Have you ever corresponded with anyone else
`about the IPR?
` A No.
` Q And by IPR, I mean IPR 2013-00401
`consolidated with IPR 2013-00404.
` Have you ever talked to Dr. Mark Tso, one of
`the inventors of the 533 patent?
` A Yes.
` Q And did your conversations concern the
`research underlying the 533 patent?
` A No. Mark Tso's a personal friend --
` Q Oh, yes.
` A -- because we move in similar academic
`circles.
` Q You see him at ARVO?
` A Yeah. We're actually in Hong Kong giving
`talks in 2012, so we were chitchatting at that time,
`not about this work. I wasn't aware of this patent.
` Q Oh, really?
` A I was aware of his published papers.
` Q Yes, yes. ARVO sponsors the Friedenwald
`lecture, if I remember correctly.
` A Yes, yes.
` Q So he gave one of those. We'll probably
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 11
`
`talk about that a little later.
` Have you ever talked with the coinventor,
`Dr. Lam, Tim-Tak Lam?
` A No.
` Q If you didn't know Mark Tso and you had
`questions about the 533 patent, to whom would you talk?
` Who do you think would have expertise in the
`area of the Tso patent, of the 533 patent?
` MR. WERNER: Objection to form.
` MR. DARBY: You answer.
` MR. WERNER: If you can understand the
` question, you can answer. If you need
` clarification, feel free to ask for clarification.
` THE WITNESS: I don't follow what you mean
` by that.
`BY MR. DARBY:
` Q Let's say you're a grad student and you read
`the 533 patent and you wanted to know more but the
`faculty at your school knew nothing about it --
` A Yes.
` Q -- or they were in a different area of
`ophthalmology --
` A Yes.
` Q -- do you know anyone that you would seek
`out to explain the 533 patent?
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 12
`
` MR. WERNER: Objection to form.
` THE WITNESS: Yes, myself.
`BY MR. DARBY:
` Q Other than yourself --
` A What I would do first -- I think most
`scientists would do a literature search on Pub Med and
`track down the original references, read the original
`references, and then if you had questions, then seek
`out -- usually what most people do is contact the
`senior author directly. Nowadays with e-mail you can
`do that, and most scientists are more than happy to
`discuss their science.
` Q Does anyone come to mind that has worked in
`the area of antioxidants and retinal degeneration?
` A There's a whole slew of people. Do you want
`a list of people?
` Q The top two or three people on your list.
` MR. WERNER: I'll just object to form.
` THE WITNESS: Peter Campochiaro at Johns
` Hopkins, Emily Chew at National Eye Institute are
` the two I would think of.
`BY MR. DARBY:
` Q Uh-huh. Thank you. And they have published
`in this area?
` A Yes.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 13
`
` Q Have you published in the area of
`antioxidants?
` A Not directly in the area of antioxidants but
`related areas.
` Q Particularly rhodopsin --
` A Yes.
` Q -- genetics of rhodopsin?
` A Yes, and rhodopsin biochemistry.
` Q In your publications about photoreceptor
`degeneration, would you characterize them as
`genetics -- genetic causes of photoreceptor
`degeneration?
` MR. WERNER: Objection to form.
` THE WITNESS: Partially, yes, yes.
` MR. DARBY: Okay.
` THE WITNESS: We use genetics as a tool to
` explore biochemistry of the photoreceptor cell.
` MR. DARBY: Yes. You have a very
` interesting paper on microglia that we'll get to.
` THE WITNESS: Yes.
`BY MR. DARBY:
` Q In your opinion, is all photoreceptor cell
`death apoptotic in nature?
` MR. WERNER: Objection to form, scope.
` THE WITNESS: That's a complicated question.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 14
`
` MR. DARBY: I know.
` THE WITNESS: It's almost an unfair question
` because the answer itself is, you know, five to
` eight hours of discussion.
`BY MR. DARBY:
` Q Uh-huh. So it's a complicated area?
` A It is, so partially. As you may be aware,
`there's other forms of cell death that occur in every
`part of the body, including the retina, so apoptosis is
`just one form of cell damage.
` Q Apoptotic processes and necrotic
`processes --
` A And something called --
` MR. WERNER: I'm going to object to form.
` This is kind of in a conversational mode, but I'm
` objecting to form and scope on this topic.
`BY MR. DARBY:
` Q Are there other degenerative and cell --
`photoreceptor cell death processes other than apoptotic
`and necrotic?
` A Yes.
` MR. WERNER: Objection to scope.
`BY MR. DARBY:
` Q What are those?
` MR. WERNER: Objection to scope. Can I have
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 15
` a running objection to anything about this topic
` that's never been addressed in this IPR
` proceeding?
` MR. DARBY: No. I'm going to ask you to
` object.
` MR. WERNER: Okay. All right.
` MR. DARBY: Thanks.
` THE WITNESS: Necroptosis is another
` recognized form of cell death.
`BY MR. DARBY:
` Q Would you agree that there are many ways in
`which a photoreceptor cell death can be initiated?
` A Yes.
` MR. WERNER: Objection to scope.
`BY MR. DARBY:
` Q In your opinion, does all photoreceptor cell
`death begin with degeneration?
` MR. WERNER: Objection to form and scope.
` THE WITNESS: That's also a difficult
` question to answer, right, because of the
` complexity of the initiating events, right?
`BY MR. DARBY:
` Q Yes, but other than an extirpation
`surgically of a photoreceptor cell, the process of --
`does the process of photoreceptor cell death occur over
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 16
`
`a period of time?
` MR. WERNER: Objection to form, scope.
` THE WITNESS: Yes.
`BY MR. DARBY:
` Q In your opinion, what is the shortest period
`of time in which a photoreceptor cell dies from
`degeneration after insult or damage?
` MR. WERNER: Objection to form and scope.
` THE WITNESS: It depends on the disease,
` right? There are certain catastrophic diseases of
` the retina like a stroke, central retinal vein
` occlusion, central retinal artery occlusion, even
` retinal detachment where we know beautiful work
` that's been published to demonstrate that
` photoreceptor cells can die within 24 hours or
` less.
` There are other injuries also to the retina
` in which photoreceptor cells can die in a
` catastrophic en masse or ensemble way.
`BY MR. DARBY:
` Q In your opinion, what is the longest period
`required for a photoreceptor cell to die?
` MR. WERNER: Objection to form and scope.
` THE WITNESS: Again, it depends on the
` disease, right? Because it's one of those classic
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 17
` circumstances in all of medicine, really, where
` it's the interaction between the genetics of the
` organism; be it, a human, mouse or so on and the
` environment.
` So there are some disorders where a patient
` may be susceptible to a disease, but the process
` itself occurs over decades or a lifetime.
`BY MR. DARBY:
` Q You're familiar with the exposure of
`neonates to bright lights?
` A Yes.
` Q In a typical situation of a neonate being
`exposed to bright light, would it be a matter of days
`or weeks or months -- it would be a matter of days
`before death occurs?
` MR. WERNER: Objection to form and
` incomplete hypothetical and scope. I mean, I have
` no idea how these are relevant to anything that he
` has said in his expert declaration submitted in
` the IPR proceeding and that's the only reason
` we're here today.
` MR. DARBY: You'll see.
` MR. WERNER: I just encourage you to -- at
` some point I'll probably have to shut this down
` because we're wasting time, but I'll object to
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 18
` scope right now and hopefully we can get to topics
` that he's actually offered opinions on.
`BY MR. DARBY:
` Q So in the case of photic insult of a
`neonate -- and photic insult is an element in the
`claims.
` MR. WERNER: Neonate is a word that I
` haven't seen in any entire life and certainly not
` in any documents in the IPR proceeding.
`BY MR. DARBY:
` Q Does it take -- can it take weeks or months
`for the photoreceptor cell to die?
` MR. WERNER: Same objections.
` THE WITNESS: Yes.
`BY MR. DARBY:
` Q Would you agree there are many ways to
`initiate death of a photoreceptor cell?
` MR. WERNER: Same objections.
` THE WITNESS: Yes.
`BY MR. DARBY:
` Q And there are -- would you agree that there
`are many ways to initiate degeneration of a
`photoreceptor cell?
` MR. WERNER: Same objections.
` THE WITNESS: Yes.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 19
`
`BY MR. DARBY:
` Q In paragraph 28 of your declaration, you
`state: It is my opinion that Cyanotech and Dr.
`Schweigert have failed to demonstrate that vitamin A
`deficiency and/or xerophthalmia involve any damage,
`injury, or disease caused by oxidative attack, free
`radical damage, or photic insult.
` In fact, the literature relied upon by
`Cyanotech indicates that vitamin A does not prevent
`oxidative attack or free radical damage of the eye. As
`I do not believe free radical attack plays a role in
`xerophthalmia or vitamin A deficiency, it is my opinion
`that retinal damage or disease caused by free radical
`attack is not inherent to xerophthalmia or vitamin A
`deficiency.
` Do you agree that that was an accurate
`quote?
` MR. WERNER: Counsel, if you would provide
` the document, he could read along with you.
` THE WITNESS: I was just going to say the
` same thing. If I could take a look at it, that'd
` be great.
` MR. DARBY: Okay. I don't have a printed
` copy with me.
` MR. WERNER: I mean, should I get one?
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 20
` Because I assume you would provide the witness
` with his declaration you're deposing him about.
` He's not going to testify by memory. He's going
` to need his expert report today, I'm sure.
` MR. DARBY: Let's take a break and print it
` out.
` (A recess was taken.)
`BY MR. DARBY:
` Q Dr. Kaushal, if you would review your
`paragraph 28 in your declaration.
` A Do you know what page that's on?
` Q Six. Five to six.
` A Uh-huh.
` Q And I'm going to focus on your statement
`that you do not believe free radical attack plays a
`role in xerophthalmia or vitamin A deficiency and that
`retinal damage or disease caused by free radical attack
`is not inherent in vitamin A deficiency.
` A Yes.
` Q Okay. Do you agree with the statement that
`although the initiating event of photoreceptor cell
`death in vitamin A deficiency is different from photic
`insults as the initiating event of photoreceptor cell
`death, both initiating events share the same sequelae,
`the accumulation of opsin unable to form rhodopsin in
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 21
`
`rods or iodopsin in cones by liganding with
`11-cis-retinal?
` MR. WERNER: Objection to form and scope.
` That was a long question, so if you need her to
` read it back, feel free to do so.
` THE WITNESS: Yeah, yeah, could you?
` MR. DARBY: Read the question back, please.
` (The preceding question was read back by the
` court reporter.)
` MR. WERNER: Objection to form, scope,
` compound.
` THE WITNESS: They're different. The
` sequelae are different and the consequence is
` different because your -- in your question you
` state their inability to form the photo pigment
` with 11-cis-retinal. In the instance of vitamin A
` deficiency, that's true; but in the instance of
` photic damage, it's only a transient event. It
` reaccumulates.
`BY MR. DARBY:
` Q Do I understand correctly that you're saying
`for a period after photic insult, opsin accumulates and
`is unable to form rhodopsin because of the lack of
`11-cis-retinal?
` MR. WERNER: Objection to form, scope.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 22
` THE WITNESS: For a transient period of
` time, yes. We studied that ourselves.
`BY MR. DARBY:
` Q Yes. So what happens when opsin accumulates
`for a transient period of time or for a longer period
`of time in the photoreceptor cell?
` MR. WERNER: Objection to form, compound,
` objection to scope.
` THE WITNESS: It depends on the state of the
` retina prior to the insult, right?
`BY MR. DARBY:
` Q Let's say that -- okay, a hypothetical --
`the photic insult continues. It's not a transient
`event. Let's say it continues for the period in the
`533 patent for 24 hours. What --
` A Could I interrupt you?
` Q Yes.
` A That's not what is stated in that patent, as
`far as I understood it. The way they induce photic
`injury in that patent and in the papers, right, it's
`the same way we all induce photic injury
`experimentally, is the mice or rats, they live in
`cyclical light, 12 hours on, 12 hours off.
` Q I'm sorry. You're correct.
` A The exposure to light was only for a brief
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 23
`period of time. I believe it was two hours or less.
`You can look -- confirm that in the patent and in the
`Tso paper as well. Some people do it for even shorter
`periods of time, so it's very brief exposure. It
`wasn't a sustained exposure.
` Q Okay. I'll confirm that later. But if
`untreated -- sorry, strike that.
` In this period in which opsin accumulates
`and is unable to form rhodopsin -- we'll talk about
`cones -- sorry, rods, and I believe the same process
`occurs in cones, but there's more research on rods.
`Rods are easier to study.
` What are the sequelae following the -- based
`on the accumulation of opsin and -- and in particular
`address the involvement of reactive oxygen species as a
`result of the accumulation of opsin?
` MR. WERNER: Objection to form, compound.
` Objection to scope.
` THE WITNESS: Your question -- I just would
` say to you -- I mean, the question is so
` complicated and you've asked it at so many
` different levels, so many different things, it's
` hard to answer that.
` If you have a specific question you'd like
` to ask me, I'm happy to answer it. It's such a
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed by Lori Junker (401-110-943-3328)
`
`d2240619-8142-4724-9279-ef15a4ff13d0
`
`
`
`Shalesh Kaushal, M.D., Ph.D. - 5/2/2014
`
`Page 24
` broad question. I mean, people talk about this
` for a whole symposium, right?
` MR. DARBY: Okay.
`BY MR. DARBY:
` Q Following the accumulation of opsin, does --
` A Under what circumstance?
` Q I don't want to limit it to a particular
`initiating event, just the accumulation of opsin.
` Do high concentrations of reactive oxygen
`species appear in the RPE?
` MR. WERNER: Objection to form, scope.
` THE WITNESS: So here's what I'd say to you:
` In the instance of the wild-type retina, right,
` which is an undiseased retina, there is no
` initiation of reactive oxygen species at the level
` of the retinal pigment epithelium.
` Opsin accumulation, as it's nascently formed
` in the rod inner segment, is a natural process,
` and we've studied that in great detail and looked
` at the consequences within the retina
` holistically.
` That's why I asked you under what conditions
` are you asking opsin accumulating. Because in the
` case of a wild-type retina or your and my retina
` right now, we're producing opsin, all of us
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`www.firstchoicereporting.com
`
`First Choice Reporting & Video Services
`Worldwide Scheduling
`
`800.939.0093
`
`Electronically signed by Lori Junker (401-110-943-3328)
`Electronically signed
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
